Catalyst Pharmaceuticals Inc (CPRX)

NASDAQ
Currency in USD
24.320
-0.360(-1.46%)
Closed·
After Hours
24.000-0.320(-1.316%)
·
CPRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CPRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
24.02224.700
52 wk Range
14.75026.158
Key Statistics
Edit
Prev. Close
24.68
Open
24.4
Day's Range
24.022-24.7
52 wk Range
14.75-26.158
Volume
753.01K
Average Vol. (3m)
1.31M
1-Year Change
45.86%
Book Value / Share
6.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CPRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.000
Upside
+39.80%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

Catalyst Pharmaceuticals Inc Company Profile

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Employees
181

Catalyst Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $0.68 doubles forecast; revenue reaches $141.4M, up 43.6% YoY, surpassing expectations by $9.86M
  • Stock falls 7.97% post-earnings despite strong financials; market concerns over Fycompa's future amid generic competition
  • 2025 revenue guidance of $545-565M; Firdapse expected to contribute $355-360M, Agamry $100-110M, Fycompa $90-95M
  • Focus on expanding market penetration, particularly among cancer-associated LEMS patients; 90% of SCLC patients with LEMS remain undiagnosed
  • Conservative guidance and potential generic competition for Fycompa may temper investor enthusiasm despite strong Q1 performance
Last Updated: 05/08/2025, 09:47 AM
Read Full Transcript

Compare CPRX to Peers and Sector

Metrics to compare
CPRX
Peers
Sector
Relationship
P/E Ratio
15.0x−0.6x−0.5x
PEG Ratio
0.08−0.010.00
Price / Book
3.7x1.2x2.6x
Price / LTM Sales
5.5x18.2x3.0x
Upside (Analyst Target)
35.7%316.7%48.7%
Fair Value Upside
Unlock14.2%9.2%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.000
(+39.80% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
0.68 / 0.34
Revenue / Forecast
141.40M / 131.54M
EPS Revisions
Last 90 days

People Also Watch

21.85
ACAD
+0.74%
43.68
EXEL
-1.53%
25.19
YOU
+0.08%
309.68
UTHR
+0.04%

FAQ

What Is the Catalyst Pharmaceuticals (CPRX) Stock Price Today?

The Catalyst Pharmaceuticals stock price today is 24.32

What Stock Exchange Does Catalyst Pharmaceuticals Trade On?

Catalyst Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Catalyst Pharmaceuticals?

The stock symbol for Catalyst Pharmaceuticals is "CPRX."

What Is the Catalyst Pharmaceuticals Market Cap?

As of today, Catalyst Pharmaceuticals market cap is 3.01B.

What Is Catalyst Pharmaceuticals's Earnings Per Share (TTM)?

The Catalyst Pharmaceuticals EPS (TTM) is 1.65.

When Is the Next Catalyst Pharmaceuticals Earnings Date?

Catalyst Pharmaceuticals will release its next earnings report on Aug 06, 2025.

From a Technical Analysis Perspective, Is CPRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Catalyst Pharmaceuticals Stock Split?

Catalyst Pharmaceuticals has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.